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ABSTRACT
Integrated networks of doctors, patients, and hospitals are a major
piece of cancer governance. They enable stakeholders to pool information
and resources and achieve systematic learning. Two groups, the Children's
Oncology Group in the United States and the Europe Against Cancer
initiative, are examples of network governance. Both demonstrate learning
processes, production and dissemination of new data, financial support, and
engagement of all stakeholders. Why have these integrated networks been
successful while so many others have failed? Because both are embedded
within regulatory frameworks that ensure that the networks work properly.
Integrated networks are vulnerable when the frameworks fail to provide the
necessary resources, accountability, fairness, and participation.
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INTRODUCTION
The fight against cancer is now a timely topic. In his first State of the
Union address, President Obama endorsed a renewed fight.' Elizabeth
Edwards listed it as the next big item for the Obama administration in the
second half of his term.2 In part, the political proposals for a renewed fight
are based on the disappointing results of the first war against cancer. 3
Cancer is poised to become the leading cause of death in the United States.4
The response to the political attention from stakeholders in the fight against
cancer has been two-fold. Some contend that the results have been better
than reported and that the criticisms are not entirely fair.5 Others argue that
more could be done and point to individual therapies based on genetic
factors or more money for research as possible answers to the problem. 6 in
this current debate, much attention has been paid to medical science and
technology, and little attention has been paid to the role of inadequate
governance and ineffective use of regulatory tools as a contributing cause of
the disappointing progress against this dread disease.
This article is an interdisciplinary and international comparative study.
The authors include a law professor, a political scientist, and a medical
oncologist. The team examined developments in the organization of cancer
and health care in the European Union and the United States over several
decades. They used archival research of governmental reports, analyzed
medical studies, looked at regulatory and legal literature, and conducted in-
person interviews.
1. See President Barack Obama, Annual Message to the Congress on the State of the Union
(Jan. 27, 2010), available at http://www.whitehouse.gov/the-press-office/remarks-president-state-
union-address (encouraging increased funding for basic research that could lead to innovative
cancer treatments).
2. Elizabeth Edwards, Op-Ed., Fight Cancers, Win Elections, N.Y. TIMES, July 18, 2010, at
WK8. Elizabeth Edwards sadly lost her own battle with cancer on December 7, 2010. See Jan
Hoffman, Elizabeth Edwards Through Many Eyes, N.Y. TIMES, Dec. 12, 2010, at WK4 (detailing
the many facets of Elizabeth Edwards' life).
3. See Guy. B. FAGUET, THE WAR ON CANCER: AN ANATOMY OF FAILURE, A BLUEPRINT
FOR THE FUTURE 1 (2005) (noting that little progress has been made in the "War on Cancer" since
it began with the enactment of the National Cancer Act of 1971).
4. Leading Causes of Death, CTRS. FOR DISEASE CONTROL & PREVENTION,
http://www.cdc.gov/nchs/fastats/1cod.htm (last visited Jan. 7, 2011).
5. See generally Susan M. Gapstur & Michael J. Thun, Progress in the War on Cancer, 303
JAMA 1084, 1084-85 (2010) (arguing that in evaluating the result of the war on cancer, critics
should take into consideration the fact that cancer is "a pleomorphic, complex, and highly
adaptable disease" and that the aging population makes cancer statistics look worse than they
actually are).
6. See generally Alan G. Thorson, Progress in Cancer Care: A Rational Call To Do Better,
60 CANCER J. FOR CLINICIANS 7, 10 (2010) (indicating that a lot of progress has been made in the
war on cancer, but that consistent investments of time and resources into cancer research are
crucial to accelerating the slow pace of progress).
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This article is based on an analysis of two successful projects to
improve cancer care outcomes. The first project is the Children's Oncology
Group based in the United States. The second is the Europe Against Cancer
initiative. This article documents how well-organized networks of experts
using data, coordinating research, and guiding clinical care can obtain good
results.7 It also demonstrates that when broader institutional support for
these networks is weakened, the ability to continue to produce good results
declines.8 It is a counter-intuitive result for many who do not see how
governmental action and structures can produce better results for cancer
patients. An important study recently issued by the prestigious Institute of
Medicine (IOM) on cancer trials linked poor results in cancer trials to the
ill-coordinated and disorganized system currently functioning in the United
States.9 The fact that this study has been widely reported and discussed in
both the popular and medical media10 indicates that there may be a broader
understanding emerging that legal and policy tools are important in
achieving better care and outcomes. 1
This article is organized into four sections. The first Part discusses the
history of the institutional fights against cancer in the United States and the
European Union. 12 The second Part describes two integrated networks that
are linked to the governmental campaigns against cancer: 13 the Children's
Oncology Group in the United States, and the Europe Against Cancer
initiative in the European Union. It describes how these networks share
7. See infra Parts II-IV.
8. See infra Parts 11-111.
9. See generally SHARYL J. NASS ET AL., INST. OF MED., A NATIONAL CANCER CLINICAL
TRIALS SYSTEM FOR THE 21ST CENTURY: REINVIGORATING THE NCI COOPERATIVE GROUP
PROGRAM 7, 10 (2010) (reviewing the cancer trial system in the United States and concluding that
the process is inefficient and counterproductive, and often leads to unacceptable delays, due in
part to problems in government oversight).
10. See generally, e.g., Peggy Eastman, IOM Report: NCI Clinical Trials Cooperative Group
Programs Needs Urgent Retooling, ONCOLOGY TIMES, May 10, 2010, at 13-14 (finding that the
IOM report's suggestions for increased funding, reimbursement to clinicians, and consolidation of
administrative functions are necessary to address the cooperative group program's defects);
Editorial, Faltering Cancer Trials, N.Y. TIMES, Apr. 25, 2010, at WKI I (reporting on the IOM
study and noting particularly that many government-subsidized trials are not completed, and citing
regulatory inefficiency as a major reason so many trials are left incomplete); Robert C. Young,
Cancer Clinical Trials-A Chronic But Curable Crisis, 363 NEw ENG. J. MED. 306, 307-08
(2010) (noting that the IOM report recommended consolidating administrative and management
functions, improving prioritization of trials, and increasing funding to resolve inefficiencies in the
clinical trials program).
11. See generally Young, supra note 10, at 307-09 (discussing the IOM recommendations to
improve cancer trials and noting particularly the legal and policy components of the report);
Faltering Cancer Trials, supra note 10 (highlighting the regulatory and policy components of the
IOM recommendations).
12. See infra Part I.
13. See infra Part II.
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three aspects that contribute to their effectiveness: production and
dissemination of data, financial support for research and treatment, and
engagement of stakeholders. 14  Part three explains why regulatory
frameworks in which networks are embedded are necessary for continued
improvement and learning. 15 It demonstrates that regulatory frameworks
can provide accountability for performance, coordinate stakeholder
participation, support physician decision-making, and guarantee fairness of
data. 16 It also explains that if the regulatory frameworks fail to adequately
accomplish the tasks and utilize the available governance tools, the
networks will not achieve their potential. The final Part discusses how, in
the United States and the European Union, there is an emerging
understanding that, as the fight against cancer is renewed, institutional
structures and regulation are key tools.17 The frameworks must be
strengthened. In both regions, medical and political leaders are initiating
legislative and regulatory initiatives. 18
I. THE EARLY UNITED STATES AND EUROPEAN UNION CONTEXT
The history of cancer programs in the United States and the European
Union demonstrates how governance can affect cancer outcomes. Both
regions share a vision of regulatory frameworks that would enable the
production of new knowledge, transference of that knowledge, and
utilization in patient care. 19 The motivating forces behind this vision were
networks of medical experts and important political leaders.
In his 1971 State of the Union address, President Richard Nixon asked
Congress for appropriations "to launch an intensive campaign to find a cure
for cancer. . . ."20 The commitment took the form of the National Cancer
Act of 1971,21 which led to increased funding for cancer research. 22 The
14. See infra Part 11.
15. SeeinfraPart1ll.
16. See infra Part Ill.
17. See infra Part IV.
18. See infra Part IV.
19. See generally HELENA LEGIDO-QUIGLEY ET AL., ASSURING THE QUALITY OF HEALTH
CARE IN THE EUROPEAN UNION: A CASE FOR ACTION xiv (2008) (describing the connections
between public health research and policy decisions); see also NASS, supra note 9, at 7-10
(examining the NCI's clinical trials program and finding that strengthening administrative
frameworks and infrastructure would promote the production of new research leading to better
patient care).
20. President Richard Nixon, Annual Message to the Congress on the State of the Union (Jan.
22, 1971), available at http://www.presidency.ucsb.edulws/index/php?pid=3 110.
21. National Cancer Act of 1971, Pub. L. No. 92-218, 85 Stat. 778 (1971) (codified in
scattered sections of 42 U.S.C.).
22. John T. Kalberer, Jr. & Guy R. Newell, Jr., Funding Impact of the National Cancer Act
and Beyond, 39 CANCER RES. 4274, 4274-75 (1979).
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original vision of the National Cancer Act (NCA) gave the National Cancer
Institute (NCI) the responsibility and authority to coordinate all cancer-
related activities. 23 The NCI was expected not only to support basic
research, but also to provide leadership in translating scientific findings into
actual improvement in bedside cancer care.24 By the 1980s, the NCI began
providing financial support to institutions that perform basic, clinical, and
epidemiological research.25 Institutions that received these grants were
designated Comprehensive Cancer Centers.26 These Centers were expected
to boost translational research and to help disseminate newly-developed
treatments and interventions to community physicians.27 Before and after
the 1971 legislation, NCI also established grant-supported cooperative
research groups to bolster translational research.28 A typical cooperative
research group includes members such as Comprehensive Cancer Centers
and non-NCI-designated academic cancer centers around the country. The
hope was that, through cancer centers and cooperative research groups,
researchers and clinicians would collaborate to ensure wide adoption of new
standards of practice, thus bridging the critical gap between science and
treatment, and bringing real improvement to the cancer care system. 29
The European Union's anti-cancer efforts are based on a different set
of circumstances than those of the United States. 30 The authority to provide
23. §§ 2(b), 407(a), 85 Stat. at 779.
24. NAT'L CANCER POLICY BD., INST. OF MED. & COMM'N ON LIFE SCI., NAT'L RESEARCH
COUNCIL, ENSURING QUALITY CANCER CARE 19 (Maria Hewitt & Joseph V. Simone eds., 1999).
25. See generally NAT'L CANCER INST., U.S. DEP'T HEALTH & HUMAN SERVS., DECADES OF
PROGRESS 1983 To 2003: COMMUNITY CLINICAL ONCOLOGY PROGRAM 7-10 (2004), available
at http://prevention.cancer.gov/files/programs-resources/pubs/ccop20th/book.pdf (providing a
brief history of NCI's Community Clinical Oncology Program, which began in the early 1980s
and funds hospitals and medical centers engaged in cancer research and clinical trials).
26. Kalberer & Newell, supra note 22, at 4275.
27. Id. at 4279.
28. See Y. Nancy You et al., Operative Trials: The Opportunity Beckons-An Update on the
American College of Surgeons Oncology Group, 139 SURGERY 455, 456 (2006) (providing a list
of NCI cooperative group programs founded between 1956 and 1999); see also NCI's Clinical
Trials Cooperative Group Program, NATIONAL CANCER INSTITUTE (Nov. 23, 2009),
http://www.cancer.gov/images/documents/448cl 3d2-2b94-452b-81 70-44c7a04970e8/Fs l_4.pdf
(detailing the Clinical Trials Cooperative Group Program).
29. See NCI's Clinical Trials Cooperative Group Program, supra note 28 (noting that
cooperative groups comprising researchers, community physicians, and cancer centers are
designed to collectively research and promote new cancer treatments and preventions).
30. Compare, e.g., Kevin McCarthy, Foreword I of LEGIDO-QUIGLEY ET AL., supra note 19,
at xiii (noting that the European Union's efforts to provide high quality health care are the result
of increased interconnectedness between health care systems and policies), with Karen Davis,
Foreword II of LEGIDO-QUIGLEY ET AL., supra note 19, at xvii (finding that the need for
transparency and accountability in the United States' health care system led to its "quality
improvement movement").
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health care is based almost entirely in the member states,3 1 and health care
quality performance has varied by geography and types of cancer. 32
Starting in 1985, the European Union launched the Europe Against Cancer
initiative (EAC). 33 The EAC was an elaborate plan developed by
epidemiologists from across the European Union, who, with the support of
key political leaders, secured modest funding for the development of new
agencies and research.34 The goal was to improve the cancer care outcomes
in each member state by linking the state-level networks and institutions
together and creating a bank of information that included health data from
across Europe. 35 The EAC is considered the pioneering program for using
the European Union as a platform to coordinate healthcare across the
member states.36
II. INTEGRATED NETWORKS
This section discusses the development and achievements of two
integrated networks, the Children's Oncology Group in the U.S. and the
EAC initiative. These two networks have been successful in integrating
learning and practice. 37
Through the Children's Oncology Group, significant improvement in
survival for Acute Lymphoblastic Leukemia (ALL) has been achieved. 38
The five-year survival rate for ALL jumped from nearly 15 percent to over
60 percent between 1969 and 1975, and has now reached about 80
31. Herbert E. G. M. Hermans, Cross-Border Health Care in the European Union: Recent
Legal Implications of 'Decker andKohil', 6 J. EVALUATION CLINICAL PRAC. 431,432-33 (2000).
32. See Peter Boyle, Editorial, Favorable Trends in Cancer Mortality in the European Union
But No Room for Complacency, 19 ANNALS ONCOLOGY 605, 605-06 (2008) (discussing the gap
in health quality status between "old" Europe and "new" Europe and noting particularly that lung
cancer rates among Polish men are almost four times that of Swedish men); see generally C.
Bosetti et al., Cancer Mortality in the European Union, 1970-2003, With a Joinpoint Analysis, 19
ANNALS ONCOLOGY 631, 633-39 (2008) (detailing mortality rates in the European Union by type
of cancer).
33. Peter Boyle et al., Measuring Progress Against Cancer in Europe: Has the 15% Decline
Targetedfor 2000 Come About?, 14 ANNALS ONCOLOGY 1312, 1312 (2003).
34. Louise Trubek et al., The Construction of Healthier Europe: Lessons from the Fight
Against Cancer, 26 Wis. INT'L L. J. 804, 816 (2008).
3 5. Id.
36. See Frangois Briatte, The Europeanization of Health System Performance: The
EUROCARE Study and Cancer Control in England 4-5 (Apr. 15-17, 2010) (unpublished
manuscript) (on file with authors) (detailing the strong influence of the EAC programs on broader
European cancer control and on European health policy generally).
37. See Maura O'Leary et al., Progress in Childhood Cancer: 50 Years of Research
Collaboration: A Report from the Children's Oncology Group, 35 SEMINARS ONCOLOGY 484,
484 (2008) (describing the development of new treatments for Childhood Cancer Groups); Trubek
et al., supra note 34, at 814 (recounting the mission of the European-wide cancer programs).
38. O'Leary et al., supra note 37, at 484-85.
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percent.39 Some researchers argue that the biological and genetic
differences between childhood and adult cancers make childhood cancer
easier to treat.40 However, others point to the unique network among
childhood cancer researchers, clinicians and patients as the key. 41 The
childhood cancer network was created with the NCI's financial support.42
In 2000, four pediatric cancer groups merged together to form the
Children's Oncology Group (COG), one of the twelve cooperative research
groups currently funded by NCI to conduct clinical research. 43 Unlike other
cooperative groups, the Children's Oncology Group achieved substantially
higher participation rates in clinical trials and methodical comparative
effectiveness studies than other groups.44 These high participation rates
enabled researchers to improve clinical treatments without a major
breakthrough in drug development. 45 Similar multi-center and collaborative
networks can also be observed in most western European countries, where
more than 70 percent of children diagnosed with cancer participate in
national or international phase III clinical trials. 46
The EAC is another well-known example of such a network. From
1986 to 2002, three action plans, funded by the European Commission,
39. Id. at 484.
40. See JOSEPH V. SIMONE & JANE LYONS, SUPERIOR CANCER SURVIVAL IN CHILDREN
COMPARED TO ADULTS: A SUPERIOR SYSTEM OF CANCER CARE? 3, available at
http://www.iom.edu/~/media/Files/ActivityFiles/Disease/NCPF/Manuscript.pdf (explaining that
embryonic sarcomas, which are more common in childhood cancers, are more susceptible to
radiotherapy and chemotherapy than mature carcinomas, which are more common in adult
cancers).
41. See id at 5-7 (suggesting that pediatric cancer patients' participation in clinical trials-
which enable researchers to learn directly from cancer patients-is key to their increased survival
rates).
42. About the Children's Oncology Group (COG), CURESEARCH.ORG,
http://www.curesearch.org/about us/index.aspx?id=7840 (last visited Jan. I1, 2011).
43. New Cooperative Group Created to Cure and Prevent Childhood and Adolescent Cancer,
AM. CHILDHOOD CANCER ORG., http://www.candlelighters.org/Advocacy/COGmerger.aspx (last
visited Jan. 11, 2011). For more information about NCI's twelve cooperative research groups, see
Brooke Hardison Wang & Aleca Farrakh, Cooperative Groups Help Advance Cancer Research,
NAT'L CANCER INST. (Feb. 29, 2008), http://benchmarks.cancer.gov/2008/02/cooperative-groups-
help-advance-cancer-research/.
44. See Stephen J. Shochat et al., Childhood Cancer: Patterns of Protocol Participation in a
National Survey, 51 CA: CANCER J. FOR CLINICIANS 119, 128-29 (2001) (finding that children
with various forms of cancer have significantly improved chances of survival when treated at a
pediatric center, and that 94% of young childhood cancer patients are seen at either a Pediatric
Oncology Group (POG) or a Children's Cancer Group (CCG) affiliated hospital).
45. See O'Leary et al., supra note 37, at 485 (suggesting that clinical research of the type
conducted in cancer research groups-more than other factors like drug development-has been
primarily responsible for dramatic improvements in childhood cancer survival rates).
46. S. Ablett & C. R. Pinkerton, Recruiting Children into Cancer Trials-Role of the United
Kingdom Children's Cancer Study Group (UKCCSG), 88 BRIT. J. CANCER 1661, 1661-62 (2003).
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were established to combat cancer.47 The development of these action
plans, as well as the use of funding provided by the EAC, was driven by a
network of high profile epidemiologists, oncologists, patient activists, and
policy-makers. 48 The EAC is an example of a network utilizing a multilevel
monitoring system.49 This system uses tools of public reporting, league
tables, cancer registries, and practice guidelines. 50 By producing
comparative data, this multilevel system has enabled the member states to
analyze their performance on cancer outcomes. 51 This information enabled
the United Kingdom to substantially revise its cancer treatment and allocate
more funding to cancer treatment. 52 The information on the prevalence of
lung cancer assisted in the passage of a European Union law controlling
tobacco usage. 53
Successfully integrated networks not only facilitate opportunities for
collaboration,54 but also change the ways in which research is conducted,
patients are treated,56 and public health interventions are implemented.57
Examination of the stories of the Children's Oncology Group and the EAC
47. Trubek et al., supra note 34, at 814-16.
48. Id. at 816.
49. See Hadii M. Mamudu & Donley T. Studlar, Multilevel Governance and Shared
Sovereignty: European Union, Member States, and the FCTC, 22 GOVERNANCE: INT'L J. POL'Y
ADMIN. & INSTS. 73, 81 (2009) (describing the nature of multi-level governance as it relates to
cancer and tobacco control in Europe and noting that the formation of the EAC played a large role
in its development). For a detailed discussion of the notion of multi-level governance as it relates
to health care in Europe, see generally Trubek et al., supra note 34, at 820-22.
50. Trubek et al., supra note 34, at 816-18.
51. See Freddie Bray et al., The Comprehensive Cancer Monitoring Programme in Europe,
13 EUR. J. PUB. HEALTH (SUPP. 3), Sept. 2003, at 61, 61-62 (explaining how cancer data has been
used to make comparative estimates of cancer incidence, mortality, and survival in Europe).
52. See Briatte, supra note 36, at 18-19 (discussing the EUROCARE-2 study that revealed
that Britain had one of the worst cancer survival rates as compared to the rest of the developed
world and suggesting that the data were key forces driving the United Kingdom's revised cancer
policy). For more information about EUROCARE (EUROpean CAncer REgistry), see Survival of
Cancer Patients in Europe, EUROCARE, http://www.eurocare.itl (last visited on Jan. I1, 2011).
53. Council Decision 04/513, art. 1, 2004 O.J. (L 213) 8 (EC). See generally Ruth Roemer et
al., Origins of the WHO Framework Convention on Tobacco Control, 95 AM. J. PUB. HEALTH
936, 936 (2005) (discussing the adoption of the Framework Convention on Tobacco Control
(FCTC) among WHO member states).
54. See Dennis L. Kodner & Cor Spreeuwenberg, Integrated Care: Meaning, Logic,
Applications, and Implications-A Discussion Paper, 2 INT'L J. INTEGRATED CARE, Nov. 14,
2002, at 1, 2 (explaining that health care integration fosters cooperation and collaboration).
55. See Andrew C. von Eschenbach, A Vision for the National Cancer Program in the United
States, 4 NATURE REVIEWS CANCER 820, 827 (2004) (discussing the "new cancer-research
paradigm" that is developing in part due to the increasing integration of disciplines, technologies,
and tactics).
56. RoZ D. LASKER & COMM. ON MED. AND PUB. HEALTH, MEDICINE & PUBLIC HEALTH:
THE POWER OF COLLABORATION 55 (1997).
57. See id. at 105 (explaining that integrated health networks help foster collaborative efforts
that strengthen the essential functions of public health).
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demonstrate that these new practices can lead to systematic and sustainable
learning, and have large impacts. Three important practices contribute to the
success of integrated networks: production of data and dissemination of
knowledge; financial support for research; and treatment and engagement of
all stakeholders.
A. Production ofData and Dissemination ofKnowledge
An effective system of information gathering and dissemination is
essential for systematic learning. In the area of cancer care, this purpose is
often achieved through clinical trials, particularly phase III trials.58 Clinical
trials conducted at the Children's Oncology Group provided promising
results.5 9 Very high rates of patient participation in clinical trials allow the
network to compare outcomes of different interventions and improve the
overall effectiveness of cancer care. 60 "[D]ata concerning treatment and
responsiveness to treatment is gathered on each patient and analyzed by the
COG Statistics and Data Center. Research findings are then shared with the
entire COG membership and evaluated for developing new therapies."61
The Children's Oncology Group also uses epidemiological studies to
identify disparities in outcomes based on race, ethnicity, and socioeconomic
background.62
The use of clinical guidelines is essential to the dissemination of
knowledge produced in clinical trials. The Children's Oncology Group,
58. See SUZANNE H. REUBEN, PRESIDENT'S CANCER PANEL, 2004-2005 ANN. REP.,
TRANSLATING RESEARCH INTO CANCER CARE: DELIVERING ON THE PROMISE 3 (2005)
(discussing the importance of translational research, of which clinical trials are a basic element in
the fight against cancer).
59. See Shochat et al., supra note 44, at 120 (explaining that childhood cancer survival rates
are improved by, inter alia, participation in controlled clinical trials).
60. See id. at 128 (concluding that progress in the cure of childhood cancers is optimized
when affected children enter into group clinical trials); Ten Things to Know About Cancer
Treatment Trials, NAT'L CANCER INST. (Jan. 10, 2000),
http://www.cancer.gov/clinicaltrials/education/things-to-know-treatment-trials (detailing cancer
clinical trials and noting that they provide for comparison of treatment regimens).
61. COG Update, CURESEARCH.ORG (Aug. 2006),
http://www.curesearch.org/support curesearch/eblast.aspx?id=3740 (last visited Jan. I1, 2011).
62. See generally, e.g., Brad H. Pollock et al., Racial Differences in the Survival of Childhood
B-Precursor Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Study, 18 J. CLINICAL
ONCOLOGY 813, 813-20 (2000) (reporting on findings from a study of racial disparities in
childhood cancer outcomes conducted with patients in Pediatric Oncology Groups, and noting that
socioeconomic factors might also account for disparities); Sharon Worcester, Childhood Cancer
Survival: Racial Disparities Persist, INTERNAL MED. NEWS (Jan. 15, 2007),
http://findarticles.com/p/articles/mi hb4365/is 2_40/ai n29392985/ (reporting on findings from
the United States Surveillance, Epidemiology, and End Results (SEER) program that indicate that
racial disparities in childhood cancer outcomes are narrowing). See also Interview with Paul M.
Sondel, Professor of Pediatrics, Human Oncology & Med. Genetics, Univ. of Wis. Sch. of Med. &
Pub. Health, in Madison, Wis. (July 27, 2009).
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along with several other cooperative groups, publishes trial results and
preferred treatment protocols to their members.63 The Children's Oncology
Group routinely produces, revises, and distributes clinical guidelines to
ensure that most children diagnosed are treated with the best interventions
available. 64 A pediatric oncologist interviewed by the authors said the use
of clinical guidelines could be traced back to the early years of this network,
before the Internet, when most communication was conducted by mail.65
Similarly, members of the EAC network worked hard to expand and
improve existing cancer registries by forming the European Network of
Cancer Registries (ENCR).66 "These registries contained information on
cancer incidence, mortality, and prevalence from across Europe[.]" 67 The
ENCR serves as a cancer surveillance system and the information obtained
is used to develop the European Code Against Cancer.68 The Code is "a
collection of recommended protocols on cancer screening, as well as best
practices for the prevention and treatment of all cancers." 69 These protocols
"have become the industry standard in cancer treatment in Europe and are
continually updated to reflect new information on cancer control[;]" 70 they
are also used by advocacy groups to push national governments to reduce
the overall cancer burden.71
63. Clinical Trial Results: Summaries of Newsworthy Clinical Trial Results, NAT'L CANCER
INST., http://www.cancer.gov/clinicaltrials/results/type/childhood (last visited Jan. 12, 2011).
64. See NURSING DISCIPLINE CLINICAL PRACTICE SUBCOMM. & LATE EFFECTS COMM.,
CHILDREN'S ONCOLOGY GRP., ESTABLISHING AND EXCHANGING SERVICES FOR CHILDHOOD
CANCER SURVIVORS: LONG-TERM FOLLOW-UP PROGRAM RESOURCE GUIDE xii-xiii (Wendy
Landier ed., 2007), available at
http://www.survivorshipguidelines.org/pdf/LTFUResourceGuide.pdf (describing the most recent
standards and strategies for caring for childhood cancer survivors); see also COG and Its Role in
Clinical Trials, CURESEARCH.ORG,
http://www.curesearch.org/our research/indexsub.aspx?id=1472 (last visited Jan. 12, 2011)
(discussing the production of treatment guidelines and protocol); Progress, CURESEARCH.ORG,
http://www.curesearch.org/our-research/index-sub.aspx?id=1527 (last visited Jan. 12, 2011)
(detailing the most recent treatment successes resulting from COG clinical trials and research).
65. Interview with Paul M. Sondel, supra note 62.
66. See Freddie Bray et al., Estimates of Cancer Incidence and Mortality in Europe in 1995,
38 EUR. J. CANCER 99, 99-100 (2002) (describing the history and purpose of the ENCR).
67. Trubek et al., supra note 34, at 816.
68. See id. at 816-18 (explaining that information obtained through the improved registries is
used to update the European Code Against Cancer).
69. Id at 818.
70. Id
71. See id at 818-19 (noting that patient advocacy prompted the European Union to set
higher standards for cancer mortality reduction).
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B. Financial Support for Research and Treatment
Financial support is crucial in achieving sustainable network
integration. In the United States, the lack of universal health care coverage
is acknowledged as a deterrent to system improvement. 72 Inconsistent
methods of determining payment for treatments also add to difficulties in
making cancer care affordable.7 3 Insurance companies often deny coverage
for treatment through cancer trials, an obstacle that discourages many
patients from participation in these trials.74 An IOM workshop describes the
payment obstacles to recruitment for trials: "Instead of cooperation there is
competition fueled by limited financial resources and a lack of the sort of
communication that would foster more efficient alignment." 75
In contrast, the Children's Oncology Group has been able to overcome
financial obstacles through public education, advocacy, and fundraising. 76
The Children's Oncology Group locates financial resources from disparate
insurance payors.77 The Children's Oncology Group, through its
CureSearch website, provides patients and their families with information
on how to access and advocate for payment from insurance providers and
charity organizations. 78 Private insurance companies, influenced by
consistent patient advocacy, have cooperated by approving coverage for
72. See generally Karen Davis, Commentary, 60 MED. CARE RES. & REV. (SUPP.) 89S, 89S-
97S (2003) (arguing that the high number of uninsured Americans has resulted in harm to the
country and to the health care system).
73. See, e.g., Paula Kim, Cost of Cancer Care: The Patient Perspective, 25 J. CLINICAL
ONCOLOGY 228, 228-29 (2007) (describing the numerous hidden costs of cancer care and
explaining that one payment method is usually insufficient).
74. MARGIE PATLAK ET AL., INST. OF MED., MULTI-CENTER PHASE Ill CLINICAL TRIALS
AND NCI COOPERATIVE GROUPS: WORKSHOP SUMMARY 47-50 (2009), available at
http:/ibooks.nap.edu/openbook.php?recordid=1 2535&page=Rl.
75. Id at 44.
76. See CureSearch Fact Sheet, CURESEARCH NAT'L CHILDHOOD CANCER FOUND. (Apr. 9,
2008), http://www.curesearch.org/uploadedFiles/CureSearch Fact Sheet 61 22 07.pdf (stating
that the Children's Oncology Group has been able to conduct clinical trials with the support
provided by public education, advocacy, and fundraising).
77. See Resource Directory, National and International Resources: Financial Assistance,
CURESEARCH.ORG, http://www.curesearch.org/resources/resourceservice.aspx?Serviceld=1 (last
visited Jan. 12, 2011) (providing contact information for and descriptions of diverse sources that
offer financial support for cancer therapy).
78. Insurance Denials, CURESEARCH.ORG,
http://www.curesearch.org/for parentsandfamilies/newlydiagnosed/article.aspx?Articleld=3182
&Stageld= &Topicld=5&Level= I (last visited Jan. 12, 2011); Insurance Issues,
CURESEARCH.ORG, http://www.curesearch.org/forparents-and-families/
newlydiagnosed/article.aspx?Articleld=3118 (last visited Jan. 12, 2011); Tips for Dealing with
Insurance, CURESEARCH.ORG,
http://www.curesearch.org/for_parents and families/newlydiagnosed/article.aspx?Articleld=3181
&Stageld=l&Topicld=5&Level= I (last visited Jan. 12, 2001) (providing advice and guidance on
obtaining payment through insurance providers).
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participation in clinical trials. 79 The companies' rapid approval suggests
that they recognize that clinical trials are an accepted standard of care for
treatment. 80 The Children's Oncology Group also organized families,
including cancer survivors, to raise funding for care and to support specific
federal legislation for research."' The Caroline Pryce Walker Conquer
Childhood Cancer Act of 2008 is one example.82
In Europe, financial support from the European Union was crucial to
the EAC's research and information gathering function. 83 The league tables
produced by the information collected by the EAC demonstrated that the
United Kingdom had poor results in cancer outcome. 84 These EAC league
tables convinced the United Kingdom in the Blair era to fund more cancer
treatment.85 Since the introduction of increased funding, there has been an
improvement in United Kingdom cancer outcomes. 86
C. Engagement ofAll Stakeholders
Engaging network members is critical for the learning process. The
engagement of patients is especially crucial. In the Children's Oncology
Group, patient interest in clinical trials is an essential part of information
gathering. Through their careful support, oncologists and other medical
personnel at the cancer centers maximized the Children's Oncology
Group's capacity to help patients.87 The Children's Oncology Group
provided patients with trustworthy doctors and hospital centers,88 long-term
commitment to them and their families, 89 and financial support. 90 The
79. Gina Kolata & Kurt Eichenwald, In Pediatrics, a Lesson in Making Use of Experimental
Procedures, N.Y. TIMES, Oct. 3, 1999, at 40.
80. See id. (describing the success of childhood cancer clinical trials in attracting participants
and noting that this is due in part to cooperative insurance companies).
81. CureSearch Fact Sheet, supra note 76.
82. Caroline Pryce Walker Conquer Childhood Cancer Act of 2008, Pub. L. No. 110-285, 122
Stat. 2682.
83. Trubek et al., supra note 34, at 811.
84. Briatte, supra note 36, at 9.
85. Id. at 16-19.
86. See 372 PARL. DEB., H.C. (6th ser.) (2001) 718W-720W (U.K.), available at
http://www.publications.parliament.uk/pa/cm200l02/cmhansrd/vo010720/text/10720w66.htm#10
720w66.html sbhdl (detailing funding for cancer study and the coincident increase in cancer
survival rates). See also, e.g., Boyle et al., supra note 33, at 1312-13, 1315, 1317-18, 1321
(providing extensive data indicating that U.K. cancer rates have improved with an increase in
funding for research and treatment).
87. See O'Leary et al., supra note 37, at 484-85 (describing COG's long record of success in
providing childhood cancer patients with the best available cancer therapies).
88. See id. (discussing physicians' treatment of children with cancer).
89. NURSING DISCIPLINE CLINICAL PRACTICE SUBCOMM. & LATE EFFECTS COMM., supra
note 64, at xii.
90. See sources cited supra notes 77-78.
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group was also quick to inform patients about available trials and facilitated
consent for participation in such trials. 91 Many parents were willing to
travel far distances to obtain the best care. 92 As a result, there were higher
rates of clinical trial participation and a higher capacity to conduct
comparative effectiveness studies in the Children's Oncology Group than in
other cancer networks. 93
The EAC has also benefited from forms of patient activism. Various
national cancer advocacy groups, generally organized around specific
cancers, came together to form the European Cancer Patients Coalition
(ECPC). 94 The ECPC is now active across Europe, 95 and it also distributes
comparative information on outcomes on the national and local level.96 The
ECPC works closely with the researchers funded through the European
Union and advocates for continued funding. 97 In addition, the organization
91. See Resource Directory: Clinical Trials, CURESEARCH.ORG,
http://www.curesearch.org/our research/clinical trials/ (last visited Jan. 12, 2011) (providing
general information about clinical trials and links to two databases of clinical trials currently
seeking participants); Informed Consent, CURESEARCH.ORG,
http://www.curesearch.org/forparentsand families/intreatment/medical/articl.aspx?Articleld=31
22&Stageld=3&Topicld=76&Level= I (last visited Jan. 12, 2011) (explaining the process
involved in consenting to treatment through a clinical trial).
92. See, e.g., Karen H. Albritton et al., Site of Oncologic Specialty Care for Older
Adolescents in Utah, 25 J. CLINICAL ONCOLOGY 4616, 4618-19 (2007) (providing data to
indicate that many families with young children in Utah are willing to travel long distances to
receive medical treatment).
93. Compare O'Leary et al., supra note 37, at 485 (providing data indicating that higher
participation rates in childhood cancer trials has led to higher cure rates), with Misconceptions and
Lack ofAwareness Greatly Reduce Recruitment for Cancer Clinical Trials, HEALTH CARE NEWS
(Harris Interactive, Inc., New York, N.Y.), Jan. 22, 2001, at 1, available at
http://www.harrisinteractive.com/news/newsletters/healthnews/Hl HealthCareNews2001 Vol 1_iss
3.pdf (describing the low rate of clinical trial participation in other cancer networks).
94. About ECPC, EUR. CANCER PATIENT COAL. http://www.ecpc-online.org/about-ecpc.html
(last updated Oct. 6, 2010).
95. See id (explaining ECPC's current and future policy goals in the European Union).
96. See Trubek et al., supra note 34, at 833-34 (discussing ECPC's role "as an informational
router between the EU and Member States' citizens).
97. See id. (discussing ECPC's role in obtaining continued funding through the MEPs Against
Cancer (MAC) caucus). See also EUR. CANCER PATIENT COAL., ECPC ANNUAL REPORT 2009, at
15-17 (2009), available at http://www.ecpc-online.org/component/docman/docdownload/161-
ecpc-annual-report-2009.html?Itemld= 127 (discussing ECPC's goal of enlarging its funding base
and noting the coalition's EU funding and expenditures on EU related projects); ECPC Flyer,
EUR. CANCER PATIENT COAL., http://www.ecpc-online.org/component/docman/docdownload/I -
ecpc-flyer-english.html (last visited Jan. 12, 2011) (discussing ECPC's role in the Partnership for
Action Against Cancer which connects researchers with governments, patient organizations,
health professionals, and industry).
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helped develop the Members of Parliament Against Cancer (MAC) caucus
at the European Parliament. 98
III. WHY REGULATORY FRAMEWORKS ARE NECESSARY
The success of the two networks is based both on the early visionary
regulatory frameworks and the new practices that integrate learning and
standardization. These regulatory frameworks, the NCA and the EAC, were
crucial in the early development of the networks. However, in recent years,
there has been a reduction in the effectiveness of the United States and the
European Union cancer programs. 99 The ineffectiveness is based in part on
the fragmentation of the regulatory framework.100 In recent decades, the
United States regulatory framework created in the 1970s shifted away from
translational research and systematic coordination. 10 1 The NCI delegated
the goal of connecting research and clinical care to institutions like
comprehensive cancer centers and cooperative research groups. 102 The
collaboration between researchers and clinicians proved spotty and difficult
to maintain.103
Moreover, the record of achievement has been unimpressive. The
reductions in cancer mortality have been relatively weak compared to more
98. About MAC (MEPs Against Cancer), MEPS AGAINST CANCER,
http://www.mepsagainstcancer.org/index.phpoption=com-content&task-view&id=12&ltemid=2
7 (last visited Jan. 12, 2011).
99. See Trubek et al., supra note 34, at 826-27 (describing 2002 EAC funding cuts and
member nation difficulties); Faltering Cancer Trials, supra note 10 (describing bureaucratic
hurdles facing and the poor coordination of NCI, and how NCI is near a "state of crisis").
100. See Clifton Leaf, Why We're Losing the War on Cancer (And How to Win It), FORTUNE,
Mar. 22, 2004, at 77, 80-82 (describing the American cancer effort as "utterly fragmented" and
"increasingly narrow," with funding coming from multiple federal agencies, states, and private
industry with very little coordination).
101. See PRESIDENT'S CANCER PANEL, THE NATIONAL CANCER PROGRAM: ASSESSING THE
PAST, CHARTING THE FUTURE, 1999 ANNUAL REPORT (2000), available at
http://deainfo.nci.nih.gov/advisory/pcp/archive/pcp99rpt/99report.pdf (recounting five
amendments to the National Cancer Act from 1971 to 1993 that increased NCI's research capacity
without improving information delivery systems). For a more detailed understanding of what
translational research entails, see generally Steven H. Woolf, The Meaning of Translational
Research and Why It Matters, 299 JAMA 211, 211-13 (2008). Dr. Woolf points out that there are
currently two different areas of research called "translational." Id. at 211. The first "refers to
translating research into practice," and "ensuring that new treatments and research knowledge
actually reach the patients[.]" Id. The second form of translational research attempts to
"reorganiz[e] and coordinat[e] systems of care," and help "clinicians and patients to change
behaviors and make more informed choices." Id.
102. See FAGUET, supra note 3, at 99-101 (discussing NCI's delegation of research tasks to 39
Comprehensive Cancer Centers and noting that it has spent as much as $252.2 million (5.5% of its
total operating budget) in 2003 on cooperative trials).
103. See PRESIDENT'S CANCER PANEL, supra note 101 ("Simply put, we are not applying what
we know-interventions demonstrated to be efficacious and validated through the clinical trials
process-nearly well enough, quickly enough, or widely enough.").
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rapid progress in heart disease and other major health threats. 104 Progress
across different types of cancers and across geographic areas has been
uneven, with mortality and disability substantially reduced for some but not
for others.10 5 After almost 40 years106 and $200 billion' 0 7 spent on cancer
research, the return on the nation's investment is disappointing."0 In 2010,
an estimated 1,529,560 new cancer cases will be diagnosed,109 and an
estimated 569,490 Americans will die from cancer.' 10 Globally, cancer is
poised to become the leading cause of death. 11
Today, many cancer experts acknowledge that improved outcomes
require a wide spectrum of activities: basic research, translational research,
clinical care, and public health-based cancer control programs. 112 Analysts
often attribute the unsatisfactory outcome of the first war on cancer to an
overwhelming focus on basic research and the dominance of a "cell-kill
paradigm." 1l3 A recent IOM report on cancer clinical trials system argued
that the "complex trials system has become inefficient and cumbersome"
and that "a robust, standing cancer clinical trials network is essential to
effectively translate discoveries into clinical benefits for patients."I14 So
104. See Gina Kolata, In Long Drive to Cure Cancer, Advances Have Been Elusive, N.Y.
TIMES, Apr. 24. 2009, at Al (reporting that the death rate for cancer dropped by 5 percent
between 1950 and 2005, while the death rate for heart disease fell by 64 percent and the death rate
for flu and pneumonia by 58 percent). Compare AM. CANCER SoC'Y, CANCER FACTS & FIGURES
2010, at 2 (2010), available at
http://www.cancer.org/acs/groups/content/@nho/documents/document/acspc-024113.pdf
(charting incidents of cancer-related mortality in the United States), with NAT'L HEART LUNG &
BLOOD INST., FACT BOOK FISCAL YEAR 2006,35-51 (2007), available at
http://www.nhlbi.nih.gov/about/factbook-06/06factbk.pdf (charting incidents of heart and other
major disease-related mortality in the United States).
105. See AM. CANCER SOC'Y, supra note 104, at 40-41 (discussing variability in lung cancer
rates across the United States); Kolata, supra note 104 (discussing variability in life expectancy
between colorectal, prostate, and lung cancers).
106. See Sharon Begley with Anne Underwood, Jeneen Interlandi & Mary Carmichael, We
Fought Cancer . .. And Cancer Won, NEWSWEEK, Sept. 15, 2008, at 42 (noting that President
Richard Nixon declared war on cancer in 1971).
107. Id.
108. See id. ("[T]he scientists and physicians whom Nixon sent into battle have come up short.
Rather than being cured, cancer is poised to surpass cardiovascular disease and become America's
leading killer . . . . [1]n 2008, cancer will take the lives of 230,000 more Americans-69 percent
more-than it did in 1971.").
109. AM. CANCER SOC'Y, supra note 104, at 1.
110. Id
111. Id at 52.
112. REUBEN, supra note 58, at i-ii, xi-xii, xvi (discussing NCI's recommendations for a more
effective national cancer research network, ranging from greater research coordination to
information dissemination in local clinics).
113. See FAGUET, supra note 3, at 63-64 (discussing at length the "cell-kill paradigm,"
including its misconceptions and resulting drug inefficacy).
114. NASS ET AL., supra note 9, at 2. See generally Young, supra note 10, at 307-09
(explaining that NCI's clinical trial program is cumbersome and ineffective, and summarizing
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even though the Children's Oncology Group has managed to conduct the
trials, its experience cannot be effectively transferred to the broader cancer
enterprise. There is no effective, multilevel monitoring structure that can
provide that function.
Despite its initial success, the EAC was not completely refunded in
2002, and, as a result, the program languished.' 15 The European Union
health programs grew in the first decade of the 2 1st century,"l6 but the
cancer control process was put on hold.' 17 The EAC functioned under an
European Union Commission planning document that integrated member-
state programs with European Union funding and institutions."' After the
Commission's early success, European Union funding and Commission
commitment were reduced in 2002.'19 The Commission thought that the
member states would take over the funding and planning.120 However, the
member states saw the EAC as a permanent element in a multilevel
project.12 1 Without the European Union resources, the network was in
danger of collapsing.122 The multilevel, monitoring function that had been
previously provided by the European Union Commission's plan and
personnel, plus the funding for the research function, proved essential for
the EAC to thrive. 123
IOM's recommendations to improve trial efficiency, prioritization, and physician and patient
participation).
115. Trubek et al., supra note 34, at 826.
116. See id. at 827 (describing the growth of EU health programs and the shift to research in
emerging areas such as cardiovascular disease, diabetes, and mental health).
117. See id. at 826 (noting that EU funding for the EAC ended in 2002).
118. Resolution of the Council and the Representatives of the Governments of the Member
States, Meeting within the Council of 7 July 1986, on a Programme of Action of the European
Communities Against Cancer, 1986 O.J. (C184) 19, 20, available at http://eur-
lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:41986XO723(04):EN:HTML. See also
Trubek et al., supra note 34, at 814-16 (chronicling various EU action plans designed to
"coordinate[] exchanges of information and expertise between cancer specialist health
professionals across the EU[,]" as well as the strategic use of funding made available to the EAC).
119. Trubek et al., supra note 34, at 826.
120. Id. at 827.
121. See id. at 827-28 (explaining that Member States saw the fight against cancer as
Europeanized); see also John Illman, Funding Cuts for Public Health Projects in Europe May
Affect International Cancer Effort, 96 J. NAT'L CANCER INST., 428, 428 (2004), available at
http://jnci.oxfordjournals.org/content/96/6/428.full.pdf+html (quoting Richard Sullivan, M.D.,
Ph.DI, head of clinical programs at Cancer Research U.K., who explained that "[w]hen
EUROCARE was cut off at the knees, it was told to go to member states for money but, in effect,
the member states said: 'Don't be ridiculous. This is a European issue."').
122. See Trubek et al., supra note 34, at 827-28 (describing Member States' unwillingness to
take over funding and coordinating responsibilities from the EU).
123. See id. at 811-14 (arguing that the EAC's "iterative and reflexive system of network
governance" proved "instrumental in guiding the EU's activity in cancer").
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Why were these outstanding networks unable to stabilize or serve as
exemplary projects on their own? The reason is that the regulatory
frameworks in which they were embedded proved essential to their
continued existence and integration. Once these frameworks fail to
function effectively, the networks become isolated and fragile. In the case
of the Children's Oncology Group, the fragmentation of the cancer
institutions originally coordinated by the NCI left the Children's Oncology
Group isolated. In the EAC, the drastic reduction of resources from
European Union research funds and the shift in priorities from cancer to
other health issues left the network under-resourced. 124
What are the essential elements that these frameworks provide? The
frameworks can include a mix of governmental agencies, health care
institutions, non-profit organizations, and private companies. These
frameworks can be defined as institutional conditions that create, support,
and maintain the proper functioning of an integrated learning process.
These frameworks support the web of relationships that make up the
networks. They also ensure the viability and trustworthiness of the
networks. First, the frameworks provide accountability for performance
quality. 125 Second, they monitor the openness and accessibility of the
stakeholder participation. 126 Third, they remove the barriers, economic and
otherwise, that discourage physicians from participating in the learning
process.127 Finally, they guarantee fairness in the processes that create and
provide data. 128
A. Ensuring Accountability for Performance in Networks
Networks promote the creation of data to support the production and
dissemination of relevant knowledge. In the case of the Children's
Oncology Group and the EAC, the networks themselves worked to expand
the availability of data,129 convert it into knowledge,130 and disseminate
124. Trubek et al., supra note 34, at 826.
125. See infra Part IIL.A (explaining how frameworks ensure accountability by establishing
coordination, assessing performance, and disseminating results).
126. See infra Part III.B (noting that the Childhood Cancer Group and the EAC networks
increased the influence of patients as stakeholders in the collaborative fight against cancer).
127. See infra Part Ill.C (detailing how programs like the EAC provided greater access to a
wider array of research and protocol from which clinical care physicians could reference and
learn).
128. See infra Part III.D (noting that strong oversight can help alleviate the threat of conflicts
of interest).
129. See generally O'Leary et al., supra note 37, at 484-85 (discussing the purpose and history
of the Children's Oncology Group (COG), its antecedent organizations, and the collaborative
research conducted by members); Trubek et al., supra note 34, at 816-17 (explaining how the
EAC expanded the availability of data).
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that knowledge.131 An effective framework can ensure that the networks
continually improve data collection and dissemination, and that their
learning is shared with other networks. They do this through emphasizing
coordination, creating and publishing performance measures, and
monitoring the dissemination of positive results and protocols.
1. Coordination
The path to system improvement requires policy and program
coordination at multiple levels. Many United States public health agencies,
including the NCI, the Centers for Disease Control and Prevention, the
Food and Drug Administration, the Department of Veterans Affairs, and
even the Department of Defense have jurisdiction over parts of the cancer
care system. 132 In addition, a number of voluntary organizations such as the
American Cancer Society and the American Lung Association, biotech and
pharmaceutical firms and associations, comprehensive cancer centers,
community hospitals and oncology clinics, clinical trial cooperative groups,
employers, insurers, patient advocacy groups, survivor networks, and
patients all play important roles in research and treatment. 33 This
impressive roster of participants is both a badge of honor and failure in the
United States' effort to combat cancer. The scope of participation is
impressive, but none of the participating individuals or institutions are
accountable for the full scope of the problem, nor are the participants
provided with sufficient authority and resources to be held accountable. The
combination of fragmented and overlapping authority is widely noted as a
problem in combating cancer.134 In 1993, the National Cancer Advisory
Board (NCAB) conducted an evaluation of the National Cancer Program.135
130. See generally, O'Leary et al., supra note 37, at 484-85 (describing the "pooling of
scientific ideas, patient data, and other resources" in order to facilitate collaborative research);
Trubek et al., supra note 34, at 816-17 (explaining the EAC's conversion of data into knowledge).
131. See O'Leary et al., supra note 37, at 485 (discussing the public discourse through
publications and presentations generated by collaboration in the COG); Trubek et al., supra note
34, at 817 (noting the EAC's role in disseminating knowledge from research conducted by
participants).
132. SUBCOMM. To EVALUATE THE NAT'L CANCER PROGRAM, NAT'L CANCER ADVISORY
BD., CANCER AT A CROSSROADS: A REPORT TO CONGRESS FOR THE NATION 11 (1994).
133. See id. at 11-13 (noting the role of comprehensive cancer centers, clinical trial
cooperative groups, biotech and pharmaceutical firms, advocates, health care facilities, insurers,
assorted foundations, and other voluntary organizations in the National Cancer Program);
PRESIDENT'S CANCER PANEL, supra note 101 (making note of the role of public and private
payers in the process of determining available cancer care); Finding Cures, AM. LUNG ASS'N,
http://www.lungusa.org/finding-cures (last visited Jan. 13, 2011) (describing the American Lung
Association's role in the development of research and treatments for lung cancer).
134. PRESIDENT'S CANCER PANEL, supra note 101.
135. See generally SUBCOMM. To EVALUATE THE NAT'L CANCER PROGRAM, supra note 132,
at 5-7 (summarizing the major findings of the study).
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In its report, the NCAB identified six problems hindering progress against
cancer. 136 The first and main problem was the lack of national coordination
of public, private and voluntary stakeholders. 137 One decade later,
coordination remains a fundamental barrier to improving cancer
outcomes. 3 8 In the European Union, the reduction in funding for the EAC
weakened coordination. 139 Since 2002, the regulatory framework at the
European Union level has been struggling. 140
2. Performance Assessment
Coordination is particularly important if a framework is to provide
multi-level monitoring. Many actors in the cancer network believe that
measuring the quality of cancer care is an essential first step towards
improving the quality of that care.14 1 Without performance indicators, it is
argued, there is no way to distinguish the difference between excellent,
good, adequate, and inadequate care, and, thus, no basis on which to
identify strengths and weaknesses in the system to design improvements. 142
Public reporting and pay-for-performance are two relatively "soft"
regulatory initiatives emerging in some healthcare networks that are
designed to measure the quality of care and provide incentives for quality
improvement. It is well established that performance information, like
rankings and report cards, can have a "purposeful" use in improving
existing programs and service delivery.143 "The doctrine of performance
136. Id. at 5.
137. Id. at 5, 14.
138. See PRESIDENT'S CANCER PANEL, supra note 101 ("At this time, however, there is no
consensus in either the research or health care delivery communities as to whether, or in what
manner, coordination of a total national cancer effort is possible or desirable."); Leaf, supra note
100, at 80-81 (reporting that "[t]oday the cancer effort is utterly fragmented-so much so that it's
nearly impossible to track down where the money to pay for all this research is coming from.").
139. See Trubek et al., supra note 34, at 826-28 (discussing the failure of European states to
"take up the slack" of maintaining research registries and similar data sharing initiatives after the
EAC funding was not renewed).
140. See id. (describing the cuts in funding for a number of cancer-related programs, and the
failure of the individual countries to take financial responsibility for funding a similar regulatory
framework).
141. See NAT'L CANCER POLICY BD., supra note 24, at 80 (providing reasons why different
actors in the cancer network should measure the quality of cancer care).
142. See Antonio Giuffrida et al., Measuring Quality of Care With Routine Data: Avoiding
Confusion Between Performance Indicators and Health Outcomes, 319 BRIT. MED. J. 94, 94-97
(1999) (contending that performance indicators specifically are necessary in assessing care, as
basic outcome data is inadequate to accurately evaluate care providers' records).
143. See Martin N. Marshall et al., Public Reporting on Quality in the United States and the
United Kingdom, 22 HEALTH AFF., 134, 143 (explaining hospitals' response to report card data);
Donald P. Moynihan, Through a Glass Darkly: Understanding the Effects of Performance
Regimes, 32 PUB. PERFORMANCE & MGMT. REV. 592, 593 (2009) (explaining the nature of the
"purposeful" category of performance information).
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management promised a more efficient and accountable public sector.
Performance data would be used to better allocate resources, make
decisions about strategy, reengineer processes, motivate workers, and usher
in a new era of accountability."l44 The potential impact, however, depends
on whether the incentives established by performance measures are
properly aligned with the goals-in this case, reducing the incidence of
cancer mortality and disability.
Within the cancer network in the U.S., however, utilization of these
tools has been limited to measuring how well providers adhere to cancer
screening protocols.145 For example, data is collected to determine whether
physicians are performing mammography, PSA, or PAP smear exams at the
appropriate time and intervals for individual patients. 146 Experts are
optimistic that effective indicators can also be identified to evaluate the
quality of cancer care. According to Chris Queram, CEO for the Wisconsin
Collaborative for Healthcare Quality, it is technically feasible to measure
values such as five-year survival and to track how well physicians adhere to
recommended treatment protocols.147 He notes, however, that financial,
organizational, and philosophical barriers will have to be addressed before
these initiatives are systematically incorporated into specialty services like
oncology.148
The public dissemination of performance indicators is meant to
encourage individual clinicians and institutional providers to deliver quality
care by introducing reputational incentives. 149 An example of success is the
relationship between the EAC and the ENCR which facilitated the creation
of data and subsequent use in public reporting in league tables. 150 The
ENCR system allows the EAC network to publicly monitor the
performance of member states.15' The EAC initiative measured
144. Moynihan, supra note 143, at 592.
145. See, e.g., Robert A. Smith et al., Cancer Screening in the United States, 2009: A Review
of Current American Cancer Society Guidelines and Issues in Cancer Screening, 59 CA: CANCER
J. FOR CLINICIANS 27, 38-39 (2009) (describing the results of an evaluation of cancer screening
conducted over the past two decades and needed reforms).
146. Id. at 37.
147. Interview with Chris Queram, President and Chief Exec. Officer, Wis. Collaborative for
Healthcare Quality, in Madison, Wis. (July 24, 2009).
148. Id
149. See, e.g., Gwyn Bevan & Richard Hamblin, Hitting and Missing Targets by Ambulance
Services for Emergency Calls: Effects of Different Systems of Performance Measurement Within
the UK, 172 J. ROYAL STAT. SOC'Y 161, 181, 184 (2009) (hypothesizing that a requirement to
publish comparative data will encourage service providers "to remedy serious underperformance"
in order to prevent reputational damage).
150. Trubek et al., supra note 34, at 816-19.
151. See id at 816-17 (explaining that the European Network of Cancer Registries (ENCR)
system allowed for cross-national comparisons of certain cancer care data).
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international differences in survival rates and disseminated that
"information in league tables, which clearly identified substantial
international inequities for the first time." 152 The public dissemination of
performance data also provided reputational incentives for member states to
improve their own performance. 153 For example, the league table showed
that the British had long lagged behind other member states in treating lung
cancer,154 even though the National Health Institute provides free services
for all. 155 The data motivated further studies that later revealed that many
patients do not receive treatment, not because of lack of payment, but due to
their distance from treatment locations. 156
As shown by the EAC, performance assessment can have some
positive impact if the results threaten the reputation of organizational and
community leaders. "Fear of embarrassment is perhaps the most powerful
motivator for organizational leaders."1 57 This is because reputation affects
the degree of oversight from government officials and consumer advocates
and therefore the degree of managerial discretion for leaders over resources
and operations.158 Gwyn Bevan has underscored the importance of
reputational incentives. 159 In the United Kingdom, "those who ran hospitals
152. Id. at 817.
153. See, e.g., Bevan & Hamblin, supra note 149, at 184 (discussing the application of the
"reputation pathway" as a performance-enhancing measure that successfully increased ambulance
response time in the UK).
154. See Mike A. Richards, The Size of the Prize for Earlier Diagnosis of Cancer in England,
101 BRIT. J. CANCER S125, S127 (2009) (finding that "1 -year survival rates in England (26.9%)
[were] well below the European average (36.0%) .... ). See also Sarah Boseley, UK Trails in
European Cancer Cure Survey, GUARDIAN, Mar. 24, 2009,
http://www.guardian.co.uk/society/2009/mar/24/health-cancer (reporting that cancer cure rates in
England and Scotland did "less well than most of the 15 European countries whose performance
was analysed.").
155. See 372 PARL. DEB., H.C. (6th ser.) (2001) 719W (U.K.) (statement of Yvette Cooper,
Sec. of State for Health), available at
http://www.publications.parliament.uk/cm200l02/cmhansrd/vo010720/text/1072w66.htm#10720
w66.html sbhdl (referencing NHI standards which ensure that "everyone with suspected cancer
will be able to see a specialist . . . These arrangements were guaranteed for everyone . . .").
156. Compare Neil C. Campbell et al., Rural Factors and Survival from Cancer: Analysis of
Scottish Cancer Registrations, 82 BRIT. J. CANCER 1863, 1866 (2000) (finding a correlation
between increased distance from a cancer center and survival as patients were less likely to be
diagnosed before death, and noting that the correlation remained, albeit weaker, post-diagnosis),
Neil C. Campbell et al., Impact of Deprivation and Rural Residence on Treatment of Colorectal
and Lung Cancer, 87 BRIT. J. CANCER 585, 590 (2002) (finding distance from treatment facility a
factor influencing receipt of treatment, but also noting that the degree of disease advancement at
diagnosis is the most important factor for rural patients).
157. Thomas R. Oliver, Population Health Rankings as Policy Indicators and Performance
Measures, 7 PREV. CHRONIC Dis. 1, 5 (2010), available at
http://www.cdc.gov/pcd/issues/2010/sep/pdf/10_0040.pdf.
158. WILLIAM T. GORMLEY & DAVID LEO WEIMER, ORGANIZATIONAL REPORT CARDS 123-
27 (1999).
159. Bevan & Hamblin, supra note 149, at 181, 184.
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were confident that highlighting failure would result, not in reputational
damage, but the promise of increased budgets. Such systems encourage
underperformance of the public sector."1 60 He concluded that for a system
of performance measurement to have an impact, it must be capable of
inflicting reputational damage through information that is reliable,
responsive to criticism from the organizations being assessed, understood in
broad terms by the public, and published and widely disseminated. 16 1 A
strong regulatory framework, be it NCI, private groups in the United States
or a relaunched European Union-wide fight against cancer, could provide
the infrastructure for producing the measures and the comparisons. The
monitoring that is possible requires a strong coordinated framework.
Integrated networks alone cannot provide the comparative measures.
3. Systems for Disseminating Results Throughout the Region
In the United States, most cancer patients are treated in community
oncology clinics and hospitals. 162 However, until the creation of the
National Comprehensive Cancer Network (NCCN) in 1995, these cancer
centers lacked an integrated system to incorporate information gained
through basic and translational research into community oncology
practices.163 The NCCN is an alliance of 21 of the nation's leading cancer
centers164 which collaborate independently of NCI funding to develop and
disseminate clinical practice guidelines in oncology.165 "We decided a long
160. Gwyn Bevan, Performance Measurement of "Knights" and "Knaves": Differences in
Approaches and Impacts in British Countries after Devolution, 12 J. COMP. POL'Y ANALYSIS 33,
34(2010).
161. See Bevan & Hamblin, supra note 149, at 183-84 (discussing the facets of an effective
performance measurement system that utilizes reputational components).
162. According to one source, 84% of US cancer patients are treated at community cancer
clinics. Petition to Stop Cancer Cuts Surpasses 50,000 Signatures: Petition to Be Delivered to
Congress June 23, PR NEWSWIRE, June 2, 2010, http://www.prnewswire.com/news-
releases/petition-to-stop-cancer-care-cuts-surpasses-50000-signatures-95435819.html.
163. See Ellen Okin Powers, The NCCN Guidelines: How Do They Relate to Community
Oncology Practice?, I COMMUNITY ONCOLOGY 98, 98 (2004) (explaining that the 1995
formation of the NCCN represented the first effort to develop oncology practice guidelines);
NCCN Disclosure Policy, NAT'L COMPREHENSIVE CANCER NETWORK,
http://www.nccn.org/about/disclosure.asp#Guidelines (last visited Jan. 22, 2011) (identifying
NCCN guidelines as the product of an "evidence-based process integrat[ing] ... the expert
judgment of multidisciplinary panels of expert physicians from NCCN Member Institutions.").
164. About NCCN.com, NAT'L COMPREHENSIVE CANCER NETWORK,
http://www.nccn.com/about-us.html (last visited Jan. 21, 2011).
165. See NCCN Disclosure Policy, supra note 163 (stating that the funding for the NCCN
guidelines comes from NCCN member institution dues and that the organization accepts no
industry support for direct costs of guideline development). See also Disclosure of NCCN
Organizational Relationships, NAT'L COMPREHENSIVE CANCER NETWORK,
http://www.nccn.org/about/financialsupport.asp?p=about (last visited Jan. 22, 2011) (listing NCI
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time ago that we would make our guidelines available, not only to our
academic centers but also to community oncologists and whoever else
might be able to use them in decision-making."' 66 In other words, from the
inception of the cancer center model in 1971 until the formation of the
NCCN in 1995, there was no formalized effort to influence community
oncology practices by the cancer centers themselves. However, the majority
of cancer centers do not formally participate in this development effort
because NCCN membership is expensive.167
Creating clinical practice guidelines in oncology is a critical early step
in linking the research institutions and the community clinical
establishments responsible for the majority of patient care. Additional
measures, however, are also required. Once guidelines have been
disseminated to community oncologists, there must be a mechanism to track
adherence to the recommended therapies and continued surveillance to
determine the impact of adoption of those practices in terms of improved
health outcomes. The NCCN has never monitored how well, or to what
extent, community oncologists implement their guidelines. In 2004, NCCN
CEO William McGivney said, "I don't know how well the guidelines are
adhered to in the community setting . . . . Long term, we're interested in
involving the community in reporting ... 168
Only recently, the national system for cancer collaboration through the
comprehensive cancer centers and cooperative research groups has
disseminated clinical guidelines to community oncologists through the
NCCN. And this has been done without any effort to monitor the impact of
these guidelines.169 Furthermore, there is no effort to monitor major cancer
outcomes, such as five-year survival or quality of life, at the level of
among the supporting organizations but reiterating that "all NCCN content is produced completely
independently.").
166. Powers, supra note 163, at 98.
167. Compare NCI-designated Comprehensive Cancer Centers, CANCER CTRS. PROGRAM
(Jan. 3, 2011), http://cancercenters.cancer.gov/documents/ccclist.pdf (listing forty NCI-
designated comprehensive cancer centers, a figure not inclusive of all existing cancer centers in
the United States), with Press Release, Nat'l Comprehensive Cancer Network, NCCN Survey
Analyzes Clinical Trial Accrual at Academic Cancer Centers (June 4, 2010), available at
http://www.nccn.org/about/news/newsinfor.asp?NewslD=252 (listing the twenty-one NCCN
members, twenty of which are on the NCI list).
168. Powers, supra note 163, at 99-100.
169. See id. at 100 (noting a desire to work with community oncologists at some point in the
future in order to determine whether the guidelines provide them with valuable information);
Caroline McNeil, Putting NCCN's Guidelines Into Practice: It All Depends on Data, 89 J. NAT'L
CANCER INST. 468, 469-70 (1997) (indicating that there was a plan to "creat[e] the systems to
track practice patterns and outcomes and feed them into the large NCCN database" which met
with many difficulties, e.g. system compatibility).
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community oncologists, clinical sites, or institutional providers.170 As a
result, comparative analyses of the effectiveness of different community
practices are not possible. Groups such as the NCCN appear to recognize
the importance of monitoring performance indicators and using them to
assess disparities in health outcomes, but funding this type of research is
expensive and lacking.17 1 A robust regulatory framework would monitor
the adoption of the best practices and insist that performance indicators be
institutionalized.
B. Coordinating Stakeholder Participation
The success of the Children's Oncology Group and Europe Against
Cancer networks is based, in part, on strong stakeholder participation. The
stakes for participation are obvious for doctors, hospitals, researchers, and
pharmaceutical companies. However, how and why patients can participate
is a more controversial topic. Cancer care has been an area where patient
and patient advocate participation is notable. 172  The influence of patient
advocacy has been most evident in the fight against breast cancer, where a
grass-roots mobilization of women demanding representation emerged in
the late 1980's. 173 Almost spontaneously, in different parts of the country,
organizations emerged from support groups where women met and
discussed their experiences with breast cancer.174 Their shared frustration
with the cancer network led to the formation of the National Breast Cancer
Coalition (NBCC) in 1991.175 After the formation of the NBCC, funding
170. See Sharon Begley, What You Don't Know Might Kill You, NEWSWEEK (Oct. 17, 2009),
http://www.newsweek.com/2009/10/16/what-you-don-t-know-might-kill-you.html (reporting that
there is only one community cancer center that makes detailed outcome data publicly available,
and that the NCCN compiles data on how well cancer centers follow its guidelines but will not
release information relating to specific centers).
171. Powers, supra note 163, at 100.
172. See Deborah Collyar, Science and Society: How Have Patient Advocates in the United
States Benefitted Cancer Research?, 5 NATURE REVS. CANCER 73, 73-74 fig. 1 (2005) (indicating
the growing presence of cancer patient advocacy in political, fundraising, research, support, and
watchdog capacities); Press Release, Am. Cancer Soc'y Cancer Action Network, Hundreds of
Cancer Advocates to Urge Lawmakers to Make Cancer Research and Prevention Funding a Top
National Priority (Sept. 27, 2010), available at http://www. Acscan.org/mediacenter/view/id/342/
(reporting on the lobbying efforts of cancer patients and survivors).
173. Collyar, supra note 172, at 73. But see Vicki Brower, The Squeaky Wheel Gets the
Grease: Research Funding Is Not Necessarily Allocated to Those Who Need It Most, 6 EMBO
REPS. 1014, 1014-16 & tbl.1 (2005) (suggesting that the highly visible and effective patient
advocate campaign surrounding breast cancer has led to an imbalance in funding as other diseases
with broader and arguably more devastating effects receive less).
174. See Collyar, supra note 172, at 74 fig.2 (revealing that cancer patients and advocates from
diverse backgrounds formed support groups).
175. NBBC's History, NAT'L BREAST CANCER COAL.,
http://www.stopbreastcancer.org/about/history/ (last visited Jan. 13, 2011) ("NBCC has been
revolutionizing the breast cancer community since its inception in 1991.").
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for breast cancer research increased to $11.7 million in 1991,176 $77.3
million in 1992,177 and $252 million in 1993.178 These funding increases
were almost entirely attributable to the advocacy influence. 179 Similarly,
the patient advocacy associated with the EAC strengthened the political
power of the EAC programs, both at the European Union level and within
the member states.180 The ability of the EAC to interest patients in
participating in its work was motivated by the strong commitment of the
European Union commission to the cancer program.181 The patient groups
in the European Union and the member states recognized that their work
was encouraged and often funded by the European Union1 82 When the
European Union funding lapsed in 2002, the patient groups organized to
refund the efforts and elevate cancer control again as a major issue on the
176. See Emily S. Kolker, Framing as a Cultural Resource in Health Social Movements:
Funding Activism and the Breast Cancer Movement in the US 1990-1993, 26 Soc. HEALTH &
ILLNESS 820, 829 (2004) (identifying breast cancer spending at approximately $19 million in 1990
and indicating that the funding increases began when NCCN began lobbying following its
formation in 1991).
177. Id. at 824 (finding that the efforts of the National Breast Cancer Coalition to increase
federal funding in 1991 "led to the appropriation of an additional 43 million for breast cancer
research for fiscal year 1992 .... ).
178. See MAUREEN H. CASAMAYOU, THE POLITICS OF BREAST CANCER 103-52 (2001)
(describing the strategy and success of the National Breast Cancer Coalition's lobbying efforts to
expand government funding for cancer research) See also, Kolker, supra note 176 ("Encouraged
by their initial success, activists lobbied Congress for an additional $300 million in research funds
for fiscal year 1993 . . . [increasing from] $89 million in fiscal year 1991 to $433 million in fiscal
year 1993.. .").
179. See MAUREEN H. CASAMAYOU, supra note 178. See also Kolker, supra note 176, at 824
(identifying the NBCC as "[c]ritical to the efforts of breast cancer funding" as well as the "most
forceful [organization] in publicly defining breast cancer as a problem of governmental neglect.").
180. Hildrun Sundseth & Lynn Faulds Wood, Cancer Patients - Partners for Change, in
RESPONDING TO THE CHALLENGE OF CANCER IN EUROPE 191,194-96 (Michel P. Coleman et al.
eds., 2008), available at
http://www.epha.org/IMG/pdf/Respondingto the challenge of cancer in Europe.pdf
(identifying the primary purpose of advocacy groups like the European Cancer Patient Coalition, a
patient-led organization, as "ensur[ing] that policy-makers, politicians, health professionals, the
media and the general public recognize the serious burden of cancer and the need for concerted
action. . .," including lobbying the EU on behalf of Europe Against Cancer prior to its demise in
2002).
181. Memorandum, Eur. P'ship Action Against Cancer: Contribution of EU-Funded Research
(June 24, 2009), available at
http://europa.eu/rapid/pressReleasesAction.do?reference=MEMO/09/294&format-HTML&aged=
0&language=EN (detailing the specifics of how the EU supports cancer research, the coordination
of cancer research in Europe, and its commitment to cancer education).
182. See generally Sundseth & Wood, supra note 180, at 194-95 (illustrating that patient
advocacy groups, as sophisticated politically-minded entities, are very aware of EU organizations'
roles in promoting, and most importantly funding, political action against cancer).
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European Union agenda. 183 They realized that without that framework,
their influence would wither.184
Yet the traditional justification for cancer patient involvement
continues to be categorized as patient representation or fundraising for the
medical cancer establishment. 8 5 There is a tendency to see patients and
their advocates as allies in fundraising and recruitment for research, but not
as full participants in system learning and improvement.186 For example,
the NCI has the Office of the Advocacy Relations, whose role is to locate
people to serve on the plethora of NCI program and advisory
committees.187 Martha E. Gaines, the director of the Center for Patient
Partnerships at the University of Wisconsin-Madison, indicates that there is
not a clear understanding of the role of patient representation on the
committees. 188 The lack of clarity exists on all sides: among patient
advocates, researchers and clinicians. 189 Engaging patients through
government advisory committees is also inadequate. Advisory committees
are generally unsuccessful in providing meaningful patient input because
there is a separation between the scientific expertise and the policy
development.190 The learning from the advisory committee is not easily
shared with policy initiatives and the learning process does not function.
183. Id. at 196 ("Anxious that cancer should remain firmly on the EU's political agenda
despite closure of the Europe Against Cancer programme in 2002, [the European Cancer Patient
Coalition] encouraged Members of the European Parliament to set up an informal all-party forum
MEPs Against Cancer, or MAC.").
184. See Hildrun Sundseth, Shaping EU Cancer Policy, 16 PUB. SERVICE REV.: EUR. UNION
282, 282 (2008), available at
http://www.publicservice.co.uk/article.asp?publication=European%20Union&id=353&content na
me=Oncology%2ODevelopments&article=10407 (discussing that the ECPC necessarily had to
engage Parliament in order to tackle the problem of cancer).
185. Deirdre O'Connell & Paola Mosconi, An Active Role for Patients in Clinical Research?,
67 DRUG DEv. RES. 188, 188 (2006). There are also some scholars who believe that patient
influence over the healthcare system can be strengthened through consumerism and mechanisms
like quality report cards. Patients who use report cards "act as consumers, in the sense that they
weigh information gathered outside of a pre-existing clinical relationship in selecting a new
provider." Kristin Madison, Patients as "Regulators"? Patients'Evolving Influence Over Health
Care Delivery, 31 J. LEGAL MED. 9, 19 (2010).
186. See Madison, supra note 185, at 23-24 (highlighting the fact that patients generally are
not knowledgeable and may not make the best decisions, and that few tools are available to help
inform patients).
187. See Mission & Vision, OFFICE OF ADVOCACY RELATIONS, NAT'L CANCER INST.,
http://advocacy.cancer.gov/about/mission (last visited Jan. 13, 2011) (indicating that the Office of
Advocacy Relations connects advocacy and National Cancer Institute groups to advance shared
goals).
188. Interview with Martha E. Gaines, Dir., Ctr. for Patient P'ships, Univ. of Wis. Law Sch., in
Madison, Wis. (July 8, 2009).
189. Id.
190. See David L. Weimer, The Puzzle of Private Rulemaking: Expertise, Flexibility, and
Blame Avoidance in US. Regulation, 66 PUB. ADMIN. REV. 569, 571-72 (2006) (pointing out
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The involvement achieved by integrated networks, however, goes
much deeper than fundraising or serving on advisory committees. The
networks demonstrate that when patients are an integral part of the research
project as well as collaborate in treatment, the system could deliver a
positive learning cycle that could lead to improving outcomes. Although
traditional patient advocacy performs the needed functions of fundraising
and legislation,191 the learning process functions best when patients become
active partners of the cancer care system.
A robust regulatory framework can motivate broad stakeholder
participation and ensure that the participation is continuous and equitable.
This is especially true for patient participation. The Children's Oncology
Group was formed initially because there were not enough patients for
individual investigators to conduct meaningful research. 192 Such an
intolerable status quo motivated entrepreneurial pediatric oncologists to
pool resources and share information with each other. 193 They also
developed a system to engage patients and achieve impressive levels of
clinical trial participation.194 Similar conditions do not exist in other cancer
networks, 195 and intentionally designed incentives may be necessary to
engage stakeholders. While some of the critical stakeholders in the national
cancer effort have something to gain by engaging in the learning process,196
others have something to lose. 197 Coordinating these stakeholders and
that, for advisory committees, integrating expertise into policy involves value trade-offs that
might jeopardize such committees' credibility in making impartial judgment based on committee
members' expertise).
191. Stephanie Cajigal, The Patient Revolution, 4 NEUROLOGY Now 23, 24 (2008).
192. See Steve Benowitz, Children 's Oncology Group Looks to Increase Efficiency, Numbers
in Clinical Trials, 92 J. NAT'L CANCER INST. 1876, 1876 (2000) (noting two organizations were
competing for a only small population, perhaps 8,000 to 10,000 children that are diagnosed with
cancer each year, thus necessitating the creation of one group).
193. Gregory H. Reaman, Clinical Advances in Pediatric Hematology & Oncology:
Cooperative Group Research, 3 CLINICAL ADVANCES HEMATOLOGY & ONCOLOGY 133, 135
(2005).
194. See W. Archie Bleyer, The U.S. Pediatric Cancer Clinical Trials Programmes:
International Implications and the Way Forward, 33 EUR. J. CANCER 1439, 1443 (1997) (stating
that the clinical trial participation rate for American children with cancer exceeds 70% compared
to a participation rate of only 2% for adult cancer patients).
195. See Primo N. Lara et al., Prospective Evaluation of Cancer Clinical Trial Accrual
Patterns: Identifying Potential Barriers to Enrollment, 19 J. CLINICAL ONCOLOGY 1728, 1728
(2001) (stating that only 2% to 4% of all newly-diagnosed adult cancer patients participate in
clinical trials).
196. See Carol P. Somkin et al., Organizational Barriers to Physician Participation in Cancer
Clinical Trials, 11 AM. J. MANAGED CARE 413, 414-15 (2005) (discussing the attitude of
oncologists regarding clinical trials and finding the majority of oncologists believed such trials are
good for both patients and doctors).
197. See id. at 415 (highlighting the concern of health plan leaders that the number of poorly-
designed clinical trials continues to grow, which is a tremendous waste of resources and can
threaten patient safety).
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taking steps to reduce or compensate potential costs are necessary to align
the incentives of multiple stakeholders. A regulatory framework can use the
tools of aligning incentives, overseeing the recruitment of a wide range of
stakeholders, and training the stakeholders in collaboration. The alignment
of incentives may be delivered through providing additional government
funding, changing reimbursement policy, or restricting access of
uncooperative members to important resources. 198
C. Supporting Physician Decision-making
Physicians who provide clinical care require information and
assistance to provide the best care for their patients. Their decision-making
is improved through the information produced by basic research, experience
embodied in protocols, and knowledge of appropriate clinical trials. A
substantial aspect of the success of the integrated networks is the support
they provide to clinical physicians. 199 The EAC's success in the early
period is related to the codes and protocols that it produced and
disseminated. 200 The creation of cancer registries throughout the European
Union also provided information that could be utilized by the physicians.20 1
In the COG, the clinical physicians are the essential leaders assisting each
other through their well-functioning, coordinated system.202
However, there is substantial evidence that the physicians do not
receive this support in other areas of disease. 203 A survey conducted by the
American Society of Clinical Oncology found that physicians face
198. See David L. Weimer, Stakeholder Governance of Organ Transplantation: A Desirable
Model for Inducing Evidence-Based Medicine? 4 REG. & GOVERNANCE 281, 282-83, 291, 293,
295, 298 (2010) (indicating that in the context of organ transplantation, other sources of
government funding, questions about the fairness of access to rulemaking, and reimbursement
considerations have influenced incentives).
199. See NAT'L CANCER INST., supra note 28 (indicating that researchers, cancer centers, and
community physicians work together to support clinical trials).
200. See Peter Boyle et al., European Code Against Cancer and Scientific Justification: Third
Version (2003), 14 ANNALS ONCOLOGY 973, 977 (2003) (indicating that, given the rising number
of cancer cases in Europe, the European Code Against Cancer was introduced to reduce cancer
incidence and improve outcomes).
201. See EUR. COMM'N, EUROPE AGAINST CANCER: OPTIMISATION OF THE USE OF
REGISTRIES FOR SCIENTIFIC EXCELLENCE IN RESEARCH 1 (2008), available at
http://cordis.europa.eulfp7/coordination/pdf/eurocourseen.pdf (stating that cancer registries have
been essential in strengthening the quality and access to cancer occurrence and outcome
information).
202. Julie A. Ross & Andrew F. Olshan, Pediatric Cancer in the United States: The Children's
Oncology Group Epidemiology Research Program, 13 CANCER EPIDEMIOLOGY, BIOMARKERS &
PREVENTION 1552, 1552 (2004).
203. See ASCO Clinical Trials Workshop Provides Guidance for Community Practices, I J.
ONCOLOGY PRAc. 8, 8 (2005) (noting that physician barriers to clinical trial participation are well-
known and thoroughly documented).
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significant barriers with respect to time, staff, and resources that hinder
patient referrals to clinical trials. 204 Physicians must keep track of
complicated entry criteria for many trials to determine which patients are
eligible for which trials, 205 identify appropriate patients, introduce the
concept of clinical trials to unfamiliar patients or providers, 206 and deal
with insurance company pre-approval processes prior to patient
participation. All of these steps must be done amidst a busy clinic with
patients waiting.207 This process is time intensive and poorly reimbursed, if
at all.208 Physicians also lack support from the academic environment. 209 A
recent IOM report quoted a cancer researcher:
[W]orking in oncology clinical cooperative groups is
frequently not well rewarded with academic recognition and
advancement . . . . [T]his is caused by a number of factors,
including: a lack of awareness by promotions committees of
what such research entails; the collaborative nature of the
research, which makes it difficult to mark individual
accomplishments; the time factor involved in clinical research;
and the under-funding of much of this effort.210
204. See id. (highlighting the financial costs, including staff and office expenses, and time
costs of conducting clinical trials).
205. See Philip P. Breitfeld et al., Web-based Decision Support for Clinical Trial Eligibility
Determination in an International Clinical Trials Network, 24 CONTROLLED CLINICAL TRIALS
702, 703 (2003) (noting that the entry criteria for clinical trials is becoming increasingly complex).
206. See Robert L. Comis et al., Public Attitudes Toward Participation in Cancer Clinical
Trials, 21 J. CLINICAL ONCOLOGY 830, 830-31, 834 (2003) (discussing the point that determining
eligibility for clinical trials may be burdensome, that physicians often need to explain the
particulars of a clinical trial to the patients, and that a high percentage of patients are unfamiliar
with many aspects of clinical trials).
207. See Ezekiel J. Emanuel et al., The Costs of Conducting Clinical Research, 21 J. CLINICAL
ONCOLOGY 4145, 4149-50 (2003) (discussing challenges and obstacles discouraging physicians
from enrolling patients into clinical trials); Ana S. Iltis, Costs to Subjects for Research
Participation and the Informed Consent Process: Regulatory and Ethical Considerations, 26 IRB:
ETHICS & HUM. RES., Nov.-Dec. 2004, at 9, 11-12 (noting that physicians have very busy
schedules and that a discussion of cost and reimbursement with individual patients may not be the
best use of a physicians' time).
208. See Iltis, supra note 207, at II (stating that a discussion of cost and reimbursement with
patients may not be ideal when physicians already have such busy schedules and costs vary from
patient to patient); IOM Releases Recommendations for Cancer Clinical Trials,
HEMONCTODAY.COM (Apr. 16, 2010), http://www.hemonctoday.com/article.aspx?rid=63268
(noting that over a ten year period the per-case reimbursement had not increased and reflected, in
2005, only about a third of the actual cost per case).
209. See Lenore M. Buckley et al., Attitudes of Clinical Faculty About Career Progress,
Career Success and Recognition, and Commitment to Academic Medicine, 160 ARCHIVES
INTERNAL MED. 2625, 2627-28 (2000) (noting that career development programs are often not in
place for clinical researchers).
210. PATLAK ET AL., supra note 74, at 50.
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The knowledge that physicians need a variety of support in order to
provide the best care has been demonstrated and documented.211 Yet, the
regulatory framework that could mandate and fund such supports has not
been effectuated or has been partially dismantled.
D. Guaranteeing Fairness ofData
Strong oversight and monitoring prevents conflicts of interest.
Pharmaceutical companies often conduct or sponsor a large proportion of
clinical trials.212 As a result, actual and potential conflicts of interest affect
all phases of the clinical trials from design to data collection to reporting of
the results. 2 13 The dependence on the industry for financial support of the
trials is due to the inadequate insurance reimbursement for participants. 214
Companies often pay for the drugs and medical devices used in the trials,215
and the doctors involved in the trials do not always reveal their connection
to those commercial interests. 216 Another potential ethical concern is the
current practice of employing "ghost writers" to generate the protocols and
manuscripts that are then reviewed and approved by scientists and
clinicians.217
A recent report outlines an oversight system for conflicts in clinical
trials. 218 The report suggests expanding the purview of the institution based
regulatory system to include analyzing potential conflicts of interest. 219
This local review would be framed by federal mandates that outline
211. See, e.g., id. at 43-44 (highlighting the need for financial support and greater institutional
communication and cooperation).
212. Thomas Bodenheimer, Uneasy Alliance - Clinical Investigators and the Pharmaceutical
Industry, 342 NEW ENG. J. MED. 1539, 1539 (2000).
213. Id. at 1541 (identifying common problems relating to conflicts of interest).
214. See generally Gerardo Colon-Otero et al., Disparities in Participation in Cancer Clinical
Trials in the United States: A Symptom of a Healthcare System in Crisis, 112 CANCER 447, 450
(2008) (explaining that since NCI-sponsored clinical trials are poorly reimbursed and
pharmaceutical clinical trials are often better reimbursed, the industry tends to favor clinical trials
conducted by pharmaceutical companies).
215. Cancer Clinical Trials, NAT'L CANCER INST. (Apr. 27, 2010),
http://www.cancer.gov/images/documents/87c2 I e93-ad I e-4bfl -b44 1-1 0bc58751060/Fs2 l I.pdf.
216. See KATHLEEN M. BOOZANG ET AL., CTR. FOR HEALTH & PHARM. LAW & POLICY,
CONFLICTS OF INTEREST IN CLINICAL TRIAL RECRUITMENT & ENROLLMENT: A CALL FOR
INCREASED OVERSIGHT I (2009), available at
http://papers.ssm.com/sol3/papers.cfm?abstract id= 1515762 (explaining that the compensation
methodologies create potential conflicts of interests and thus would cause a doctor to hesitate in
revealing his or her commercial interests).
217. Duff Wilson & Natasha Singer, Ghostwriting Is Called Rife in Medical Journals, N.Y.
TIMES, Sept. 11, 2009, at B5, http://www.nytimes.com/2009/09/ 1/business/ I ghost.html?_r-2.
218. See BOOZANG ET AL., supra note 216, at 1-2 (explaining that federal regulations should
be amended and new requirements added in order to avoid conflicts in clinical trials).
219. Id. at 13.
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acceptable parameters. 220 This proposal is an example of how multilevel
frameworks can provide coordinated oversight without limiting local
variation and experimentation. 22 1 A revised institutional review board
(IRB) system could also encourage physician willingness to engage in
advance treatment. 222 The current outdated and cumbersome IRB process
is highlighted as contributing to physicians' unwillingness to engage in the
research and clinical process. 223
IV. RECONSTITUTING THE REGULATORY FRAMEWORK
There is an effort underway to reconstitute the frameworks. 224 In the
United States, the recent IOM report detailing the failures of cancer trials
indicates that the inadequacy of the framework in the United States is
evident. 225 Leaders from the cancer nonprofits such as the Lance
Armstrong Foundation, cancer researchers, and evidence-based reformers
have introduced several legislative packages that may coordinate and
strengthen the interrelationship between stakeholders and endorse new
tools.226 The organizers of these legislative initiatives envision a formal
framework embodied in a coordinated directive. The directive includes a
commitment to funding, comparative information, regulatory parameters,
and stakeholder engagement.
After the European Union funding dwindled in 2002, the EAC left key
constituencies in place around which new initiatives could be developed.
The members of the European Parliament, the patient coalition, the network
of epidemiologists that were previously funded through the European Union
Research Frameworks Program, and the pharmaceutical industry have now
rallied and are pursuing the reinvigoration of a regulatory framework.227
220. See id. at 8, 13 (explaining that a system of independent IRB's has developed to facilitate
compliance with federal review requirements).
221. See generally id at 25-33 (proposing a system of oversight which would integrate
national concerns with local practices while not disrupting such).
222. See Scott Burris, Regulatory Innovation in the Governance of Human Subjects Research:
A Cautionary Tale and Some Modest Proposals, 2 REG. & GOVERNANCE 65, 68, 70 (2008)
(explaining that the current IRB system is arbitrary, expensive, and unreliable and discourages
participation).
223. See id. at 70-74 (explaining various problems with the IRB model as it currently exists).
224. See generally NASS ET AL., supra note 9, at I (reviewing cancer trial programs in the
U.S.).
225. Id. at 2-4.
226. For example, legislation introduced in 2009 included the Oncology Care Quality
Improvement Act of 2009, H.R. 2939, 111 th Cong. (2009); the Comprehensive Care Improvement
Act of 2009, H.R. 1844, 111th Cong. (2009); the Access to Cancer Clinical Trials Act of 2009, S.
488, 11Ith Cong. (2009); and the Access to Cancer Clinical Trials Act of 2009, H.R. 716, 111th
Cong. (2009).
227. See COMM'N OF THE EUR. CMTYS., COMMUNICATION FROM THE COMMISSION TO THE
EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE
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The launch of the European Partnership Action Against Cancer in 2009
provides a planning process and perhaps new waves of funding. 228  The
partnership has laid out several ambitious goals, such as "achieving 100%
population coverage of screening for breast, cervical and colorectal cancer"
by 2013, reducing inequalities in cancer mortality by 70% by 2020, and
coordinating one-third of cancer research from all funding resources across
the European Union by 2013.229 To increase the funding from and
collaboration with the private sector, the European Commission and the
pharmaceutical industry "set up a joint initiative to support the faster
discovery and development of better medicines for patients: the Innovative
Medicines Initiative (IMI)."230 The objective is for all Member States to
have integrated cancer plans.231 The Commission's long-term goal is to
reduce cancer by 15% by 2020.232
Initiatives in both regions identify a strengthened regulatory
framework as essential for a new period of cancer governance. In
reconstituting the frameworks, the reformers are proposing to increase the
coordination and engagement of stakeholders, 233 intensify the production
and utilization of comparative information,234 and encourage accountability
through benchmarks and standardization. 235 Both initiatives also emphasize
dissemination of knowledge throughout their region to achieve equitable
AND THE COMMITTEE OF THE REGIONS ON ACTION AGAINST CANCER: EUROPEAN PARTNERSHIP
2 (2009), available at
http://ec.europa.eu/health/ph information/dissemination/diseases/docs/com_2009 291_en.pdf.
(explaining that the European Parliament and Council of the European Union have shown their
political commitment and given strategic direction to future European cancer activities and have
proposed a European Partnership for Action Against Cancer to pursue the reinvigoration of a
regulatory framework).
228. See id. (explaining that providing a framework for identifying and sharing information,
capacity and expertise in cancer prevention and control, and by engaging relevant stakeholders
across the European Union in a collective effort).
229. Id. at 5-7.
230. Memorandum, Eur. P'ship Action Against Cancer, supra note 181.
231. Id. See also COMM'N OF THE EUR. CMTYS., supra note 227, at 3 (explaining that the
objective to more effectively coordinate activities and actions taken within different policy areas
by Member States and other stakeholders, with the aim of reducing the increasing and unequal
European burden of cancer is to propose a European Partnership for Action Against Cancer).
232. COMM'N OF THE EUR. CMTYS., supra note 227, at 3.
233. Id. at 2.
234. Id.
235. See id. at 3, 7-8 (explaining that using a Healthy Life Years indicator and coordinating
the European Partnership for Action Against Cancer would help achieve these goals);
Memorandum, Eur. P'ship Action Against Cancer, supra note 181 (explaining that the European
Partnership Action Against Cancer will bring together the EU, national and regional research
programs, activities and policies).
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care for all cancer patients.236 These two initiatives promise a better fight
against cancer.
CONCLUSION
This article argues that supportive regulatory frameworks are
necessary for clinical care networks to work properly.237 Integrated
networks are vulnerable when the frameworks fail to provide the necessary
resources, accountability, fairness, and participation. 238 This research
coincides with the emergence of a substantial literature on how other
regulatory tools such as checklists, clinical guidelines, comparative
effectiveness research, and performance-incentives can play a role in
improving medical care. 239 The authors of this article believe that more
interdisciplinary research and analysis is needed to improve the governance
and performance of the health care system, including the current approaches
to cancer surveillance and treatment. Understanding how governance
shapes health outcomes is a crucial enterprise.
236. COMM'N OF THE EUR. CMTYS., supra note 227, at 3.
237. See supra Part Ill.
238. See supra text accompanying notes 126-29.
239. See generally ATUL GAWANDE, THE CHECKLIST MANIFESTO-HOW TO GET THINGS
RIGHT (2010) (making the case that the use of simple checklists before medical procedures can
significantly improve outcomes).
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